Medical Device Testing Services

About SenzaGen

SenzaGen's mission is to advance and commercialize non-animal methods for predictive toxicology, with a core focus on skin sensitization. The company has successfully commercialized its GARD®skin assay, which is an OECD-adopted (TG 442E, 497) regulatory test, and operates a GLP-compliant service laboratory for global clients. Its strategy is to leverage its validated platform to expand into adjacent toxicity endpoints, such as respiratory sensitization with GARD®air, and to deepen its service offerings with quantitative potency assessments to support next-generation risk assessment (NGRA).

Therapeutic Areas